Peregrine Capital Management LLC Acquires 47,074 Shares of Artivion, Inc. $AORT

Posted by Francis Steltz on Jul 1st, 2026

Peregrine Capital Management LLC increased its holdings in Artivion, Inc. (NYSE:AORT – Free Report) by 15.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 342,795 shares of the company’s stock after buying an additional 47,074 shares during the period. Peregrine Capital Management LLC’s holdings in Artivion were worth $12,553,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. SG Americas Securities LLC grew its stake in Artivion by 578.4% in the 4th quarter. SG Americas Securities LLC now owns 39,030 shares of the company’s stock valued at $1,780,000 after purchasing an additional 33,277 shares during the period. Vanguard Group Inc. raised its stake in shares of Artivion by 4.7% during the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Artivion by 338.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock worth $5,174,000 after purchasing an additional 94,312 shares during the period. Kennedy Capital Management LLC boosted its holdings in shares of Artivion by 19.0% in the 3rd quarter. Kennedy Capital Management LLC now owns 437,792 shares of the company’s stock worth $18,536,000 after buying an additional 70,030 shares during the last quarter. Finally, UBS Group AG boosted its holdings in shares of Artivion by 37.0% in the 4th quarter. UBS Group AG now owns 279,675 shares of the company’s stock worth $12,756,000 after buying an additional 75,606 shares during the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on AORT. Needham & Company LLC lowered their price objective on shares of Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Canaccord Genuity Group reissued a “buy” rating and set a $36.00 target price on shares of Artivion in a research report on Tuesday, June 16th. Stifel Nicolaus set a $45.00 price target on shares of Artivion in a research note on Monday, June 1st. LADENBURG THALM/SH SH raised shares of Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price target on the stock in a report on Friday, April 10th. Finally, Citizens Jmp dropped their price objective on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research note on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $44.17.

View Our Latest Research Report on Artivion

Artivion Trading Up 0.6%

Shares of Artivion stock opened at $22.53 on Wednesday. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25. The stock’s 50-day simple moving average is $25.41 and its 200 day simple moving average is $34.97. The stock has a market capitalization of $1.09 billion, a P/E ratio of 93.88 and a beta of 1.26. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86.

Artivion Profile

(Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.